



Why the Need for Active Management in this Sector?

The 90/90 Rule



Source: BIO Industry Analysis, 2016. Note: The 90/90 Rule is a concept created by Janus Henderson Investors.

The over or underperformance of winners and losers in this space, requires knowledge and expertise in the field



OUR INVESTMENT STRATEGY

AHAM World Series -Biotechnology Fund invests

Minimum 85% of the Fund's NAV in the Target Fund, Janus Henderson Horizon Biotechnology Fund

Investment targets and internal guidelines

Typical Investments

At least 80% of its Target Fund's assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Portfolio Construction and Stocks Selection

Development stage 30% - 70%

Early commercial 10% - 40%

Profitable 10% - 40%

Portfolio construction (50 - 80 public securities)

Addressing high unmet medical needs

_

High probability of clinical success

_

Attractive commercial opportunity

Significant market opportunity

_

Underappreciated sales potential

_

High margins at scale Dominant franchises

Strong free cash flow generation

Innovative pipelines

_

Efficient use of capital

Fund Facts			
Fund Category / Type	Feeder (Wholesale) / Growth		
Investment Objective	The Fund seeks to achieve capital appreciation over medium to long term period.		
Investment Strategy	The Fund will be investing a minimum of 85% of the Fund's NAV in the Target Fund and a maximum of 15% of the Fund's NAV in money market instruments and/or deposits.		
	We may substitute the Target Fund with another fund that has a similar investment		
	objective with the Fund, if, in our opinion, the Target Fund no longer meets the Fund's		
	investment objective. However, this is subject to the Unit Holders' approval before such		
	changes are made.		
Asset Allocation	 A minimum of 85% of the Fund's NAV to be invested in the Target Fund; and A maximum of 15% of the Fund's NAV to be invested in money market instruments and/or deposits. 		
Distribution Policy	The Fund is not expected to make distribution. However, incidental distribution may be		
	declared whenever is appropriate		
Minimum Investment	USD Class	MYR Class	MYR Hedged-class
	Initial: USD 10,000	Initial: MYR 30,000	Initial: MYR 30,000
	Additional: USD 5,000	Additional: MYR 10,000	Additional: MYR 10,000
Trustee	TMF Trustees Malaysia Berhad		

WARNING STATEMENT

A copy of the Information Memorandum ("Info Memo"), Supplemental Info Memo (if any), and Product Highlights Sheet ("PHS") can be obtained at aham.com.my, Investors are advised to read and understand the contents of AHAM World Series - Biotechnology Fund (or the "Fund") Info Memo dated 30 May 2024, and the corresponding PHS before investing. There are fees and charges involved when investing in the Fund. Investors are advised to consider and compare the fees and charges as well as the risks carefully before investing, Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and the past performance of the Fund should not be taken as indicative of its future performance. The Securities Commission Malaysia has not reviewed this material and takes no responsibilities for the contents of this material and expressly disclaims all liability, however arising from this material.

#GrowWithUs

Connect with Us



ahamcapital



ahamcapital

AHAM Asset Management Berhad Registration No: 199701014290 (429786-T)

Ground Floor, Menara Boustead, 69, Jalan Raja Chulan, 50200 Kuala Lumpur, Malaysia Toll Free Number: 1800 88 7080 T: +603 2116 6000 aham.com.my

